APVS 2017 Presentations PCV2 symposium now online >
Ceva hosts successful event dedicated to porcine circovirus, covering updated disease information and vaccination strategies with Circovac®, its whole-virus PCV2 vaccine for piglets, gilts and sows.
Ceva Philippines is the first country in Asia to receive Quality Recognition of the C.H.I.C.K Program >
Ceva Philippines recently received its accreditation from the international certifying body Bureau Veritas for the company’s Ceva Hatchery Immunisation Control (C.H.I.C.K) Program.
Ceva University - Master Class 2017 >
Master Class focused on 4 major respiratory diseases in poultry - Avian Influenza, Newcastle Disease, Infectious Bronchitis Diseases and Avian Mycoplasmosis.
Strong Ceva presence at APVS 2017 in Wuhan, China >
This was for Ceva an excellent opportunity to show Asian veterinarians its commitment to the swine industry, by being Gold Sponsor of the conference.
New “Swine Update” Available >
PCV Disease and its Diagnosis in Asia
Ceva shines light on the future with focus on innovation during VIV Asia 2017 >
Using an overall “C the future” theme, Ceva’s teams brought innovation to the fore during VIV Asia 2017, with the company winning the E-novation award for its C.H.I.C.K Program hatchery vaccination services quality recognized by Bureau Veritas and 2nd place for the Ceva Lung program for slaughter house lung check in pigs, both on the animal health category. Prior to VIV, Ceva hosted two Poultry...
Ceva reinforces its position in China and swine through new joint-venture with EBVAC >
In the presence of the Chinese Prime Minister, Li Keqiang and French Prime Minister, Bernard Cazeneuve, Ceva Santé Animale (Ceva) and EBVAC today signed a joint-venture agreement to create a new business, Ceva EBVAC, focused on the swine sector.
Ceva completes deal to acquire portfolio of Merial swine and cattle vaccines and nonsteroidal anti-inflammatories from Boehringer Ingelheim >
19 January 2017: Ceva Santé Animale today completed the acquisition of a diversified portfolio of products, including swine and cattle vaccines and multi-species nonsteroidal anti-inflammatories from Boehringer Ingelheim following its acquisition of Merial Animal Health.
Ceva Santé Animale Given European Commission Go Ahead to Acquire Merial Assets from Boehringer Ingelheim >
The European Commission recently gave its approval for the transfer to Ceva Santé Animale of nine products developed and currently marketed by Merial.
Ceva’s C.H.I.C.K Program receives world’s first independently audited Quality Recognition >
Our C.H.I.C.K. Program, received Quality recognition from the international testing and certification company , Bureau Veritas Group, based in Paris, France.